Prelude Therapeutics Inc (PRLD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 8M 16M 24M Q2 '25: 7M Q3 '25: 10.5M Q4 '25: 12.1M Q1 '26: 16.7M Q2 '26: 22.4M Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q2 '20: -38.2M Q3 '20: -49.4M Q4 '20: -58.8M Q1 '21: -71M Q2 '21: -87.5M Q3 '21: -100.2M Q4 '21: -113.7M Q1 '22: -122.1M Q2 '22: -123.6M Q3 '22: -123.2M Q4 '22: -123.5M Q1 '23: -122.4M Q2 '23: -125.3M Q3 '23: -128.3M Q4 '23: -132.3M Q1 '24: -137.5M Q2 '24: -142.3M Q3 '24: -143.3M Q4 '24: -139.7M Q1 '25: -140M Q2 '25: -135M Q3 '25: -121M Q4 '25: -104.6M Q1 '26: -84.1M Q2 '26: -67.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '19: -27.6M Q1 '20: -31.8M Q2 '20: -37.7M Q3 '20: -47.7M Q4 '20: -56.9M Q1 '21: -68.7M Q2 '21: -84.2M Q3 '21: -98.1M Q4 '21: -111.7M Q1 '22: -119.9M Q2 '22: -120.4M Q3 '22: -119.6M Q4 '22: -115.4M Q1 '23: -113.7M Q2 '23: -116.7M Q3 '23: -117.4M Q4 '23: -121.8M Q1 '24: -125.5M Q2 '24: -129.9M Q3 '24: -131.5M Q4 '24: -127.2M Q1 '25: -127.8M Q2 '25: -124.3M Q3 '25: -111.8M Q4 '25: -99.5M Q1 '26: -77.8M Q2 '26: -60.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q3 '20: -39.8M Q4 '20: -46.2M Q1 '21: -52.4M Q2 '21: -63.4M Q3 '21: -72.7M Q4 '21: -83.5M Q1 '22: -89.3M Q2 '22: -87.8M Q3 '22: -86.5M Q4 '22: -83.7M Q1 '23: -92M Q2 '23: -101.2M Q3 '23: -106.4M Q4 '23: -107.1M Q1 '24: -108.7M Q2 '24: -104.1M Q3 '24: -105.7M Q4 '24: -102.9M Q1 '25: -105.3M Q2 '25: -108.3M Q3 '25: -100.2M Q4 '25: -56.3M Q1 '26: -43.8M Q2 '26: -33.3M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q3 '20: -40.3M Q4 '20: -46.8M Q1 '21: -53.9M Q2 '21: -65.3M Q3 '21: -75M Q4 '21: -85.9M Q1 '22: -91.6M Q2 '22: -90.5M Q3 '22: -89.4M Q4 '22: -86.7M Q1 '23: -94.8M Q2 '23: -104.3M Q3 '23: -109.2M Q4 '23: -110.6M Q1 '24: -111.7M Q2 '24: -106.5M Q3 '24: -107.6M Q4 '24: -103.7M Q1 '25: -105.8M Q2 '25: -108.5M Q3 '25: -100.3M Q4 '25: -56.4M Q1 '26: -43.8M Q2 '26: -33.3M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '21: 46.1M Q3 '21: 46.3M Q1 '22: 47.1M Q2 '22: 47.3M Q3 '22: 47.4M Q1 '23: 47.7M Q2 '23: 56.2M Q3 '23: 67.6M Q1 '24: 75.7M Q2 '24: 75.8M Q3 '24: 75.9M Q1 '25: 76M Q2 '25: 76M Q3 '25: 76.1M Q1 '26: 82.5M Q2 '26: 98.4M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q2 '20: -20.27 Q3 '20: -21.59 Q4 '20: -4.56 Q1 '21: 0.09 Q2 '21: 5.01 Q3 '21: 9.60 Q4 '21: -2.42 Q1 '22: -2.58 Q2 '22: -2.58 Q3 '22: -2.55 Q4 '22: -2.44 Q1 '23: -2.39 Q2 '23: -2.35 Q3 '23: -2.17 Q4 '23: -2.04 Q1 '24: -1.88 Q2 '24: -1.80 Q3 '24: -1.78 Q4 '24: -1.69 Q1 '25: -1.69 Q2 '25: -1.64 Q3 '25: -1.47 Q4 '25: -1.29 Q1 '26: -1.00 Q2 '26: -0.73 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.